carbamates has been researched along with gsk2336805 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adkison, KK; Gan, J; Jones, LA; Lou, Y; Spreen, W; Wilfret, DA | 1 |
| Adkison, K; Cutrell, A; Elko-Simms, C; Gardner, S; Hamatake, R; Hong, Z; Rodriguez-Torres, M; Walker, J | 1 |
| Adkison, KK; Berg, J; Dumont, E; Elko-Simms, L; Galloway, C; Gan, J; Gardner, S; Jones, LS; Marbury, T; Saunders, J; Smith, W; Stump, PJ | 1 |
| Adkison, KK; Gan, J; Jones, LS; Lou, Y; Wilfret, DA | 1 |
| Arastéh, K; Bourgeois, S; Buggisch, P; Francque, S; Hoeben, E; Horsmans, Y; Jacquemyn, B; Kakuda, TN; Luo, D; Moreno, C; Nevens, F; Orlent, H; Schattenberg, JM; Van Remoortere, P; Van Vlierberghe, H; Vandebosch, A; Verloes, R; Vijgen, L | 1 |
| De Meyer, S; Thys, K; Van Remoortere, P; Vandebosch, A; Verloes, R; Vijgen, L | 1 |
4 trial(s) available for carbamates and gsk2336805
| Article | Year |
|---|---|
Echocardiogram study to evaluate the effect of the novel hepatitis C virus NS5A inhibitor GSK2336805 on cardiac contractility in healthy subjects.
Topics: Adult; Antiviral Agents; Carbamates; Echocardiography; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Myocardial Contraction; Valine | 2013 |
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Carbamates; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Phenotype; Polyethylene Glycols; Puerto Rico; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; United States; Valine; Viral Load; Viral Nonstructural Proteins | 2014 |
Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Area Under Curve; Biotransformation; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Gastrointestinal Absorption; Half-Life; Healthy Volunteers; Hepacivirus; Humans; Male; Metabolic Clearance Rate; Middle Aged; New York; Omeprazole; Protease Inhibitors; Proton Pump Inhibitors; Ritonavir; Valine; Viral Nonstructural Proteins; Young Adult | 2014 |
Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Ribavirin; Ritonavir; Simeprevir; Sulfonamides; Valine | 2017 |
2 other study(ies) available for carbamates and gsk2336805
| Article | Year |
|---|---|
Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment.
Topics: Adult; Antiviral Agents; Area Under Curve; Carbamates; Female; Half-Life; Hepacivirus; Humans; Liver Failure; Male; Middle Aged; Valine; Viral Nonstructural Proteins | 2015 |
Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Ritonavir; Sequence Analysis, DNA; Simeprevir; Sulfonamides; Treatment Failure; Valine | 2017 |